84,058 shares traded in first 1 1/4 hours. Even wi
Post# of 72440
Perhaps some remaining shorts are deciding it's too dangerous to stay short with the conference starting in a week (from which we may get a little additional information, but that seems rather unlikely), or perhaps they're worried there will be additional news on another clinical trial, etc?
Leo has done a fine job of catching them flatfooted recently -- first with the name and CUSIP change, and then the press release on the conference that surprisingly included information on Brilacidin-Oral Mucositis as well as for Brilacidin-Ulcerative Proctitis. They know now that he might do something they completely don't expect.
Also I agree with F1ash that change the name from the unpronounceable Cellceutix was a really good thing.